Editorial
doi: 10.1016/s0360-3016(00)00644-1.
Transmutability of dose and time. Commentary on the first report of RTOG 90003 (K. K. FU et al.)
- PMID: 10924964
- DOI: 10.1016/s0360-3016(00)00644-1
Item in Clipboard
Editorial
Transmutability of dose and time. Commentary on the first report of RTOG 90003 (K. K. FU et al.)
Int J Radiat Oncol Biol Phys.
.
No abstract available
Comment in
-
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard-fractionation radiotherapy for head-and-neck squamous cell carcinomas: first report of RTOG 9003: in regard to Fu et al. IJROBP 2000;48:7-16. Actuarial estimates of late normal-tissue effects...now!Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):563. doi: 10.1016/s0360-3016(01)01661-3. Int J Radiat Oncol Biol Phys. 2001. PMID: 11579925 No abstract available.
-
Radiation therapy oncology: in regard to Fu et al., IJROBP 2000;48:7-16.Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1148. doi: 10.1016/s0360-3016(01)02776-6. Int J Radiat Oncol Biol Phys. 2002. PMID: 11958925 No abstract available.
Comment on
-
A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):7-16. doi: 10.1016/s0360-3016(00)00663-5. Int J Radiat Oncol Biol Phys. 2000. PMID: 10924966 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
